Two oral drugs for brain lymphoma in older adults
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two oral medications (zanubrutinib and lenalidomide) for older adults with a certain type of brain lymphoma. The goal is to see if this treatment can help control the disease with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 70 years or older.
- You must be considered 'frail' based on a standard geriatric assessment (e.g., limitations in daily activities or significant health issues).
- You must have a specific type of lymphoma (DLBCL) that is only in your brain or spinal cord, and it must be newly diagnosed.
- You must be able to have a lumbar puncture (a procedure to take a sample of spinal fluid).
- Your overall health should be generally stable, with acceptable blood counts, liver, kidney, and blood clotting function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs — high-dose methotrexate, thiotepa, and zanubrutinib — for people newly diagnosed with primary central nervous system lymphoma (PCNSL). The goal is to see if this combination is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This trial tests a new drug called zanubrutinib combined with standard chemotherapy for people newly diagnosed with a type of brain lymphoma. The goal is to see if this combination works better than chemotherapy alone.
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Hear when a new Lenalidomide trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.